|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US7077176B2
(en)
|
2003-04-28 |
2006-07-18 |
Medical Instill Technologies, Inc. |
Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
WO2007127286A2
(en)
*
|
2006-04-24 |
2007-11-08 |
Medical Instill Technologies, Inc. |
Needle penetrable and laser resealable lyophilization device and related method
|
|
WO2009126558A1
(en)
*
|
2008-04-10 |
2009-10-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
|
|
EA022201B1
(ru)
*
|
2008-04-11 |
2015-11-30 |
Мерримак Фармасьютикалз, Инк. |
Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
|
|
CA2734265C
(en)
|
2008-08-20 |
2017-12-19 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
JP5677972B2
(ja)
*
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
WO2011098644A2
(es)
|
2010-02-09 |
2011-08-18 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones para el tratamiento de enfermedades infecciosas y tumorales
|
|
ES2724778T3
(es)
|
2011-06-10 |
2019-09-16 |
Bioverativ Therapeutics Inc |
Compuestos procoagulantes y procedimientos de uso de los mismos
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
SE1450130A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
|
|
EP2583680A3
(en)
|
2011-10-21 |
2013-06-12 |
Abbvie Inc. |
Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
|
|
WO2013090405A1
(en)
*
|
2011-12-16 |
2013-06-20 |
The J. David Gladstone Institutes |
Compositions and Methods For Inhibiting Immunodeficiency Virus Transcription
|
|
CN111499761A
(zh)
|
2012-01-12 |
2020-08-07 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
US10202595B2
(en)
|
2012-06-08 |
2019-02-12 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
AU2013290173B2
(en)
|
2012-07-11 |
2018-02-15 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
KR101520383B1
(ko)
|
2012-08-02 |
2015-05-15 |
에이비온 주식회사 |
Ｈｐｖ 감염과 관련된 암의 치료용 조성물
|
|
KR101363576B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
알츠하이머 질환에 대한 신규 바이오마커 및 그의 용도
|
|
KR101363575B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
신부전증에 대한 신규 바이오마커 및 그의 용도
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP2908847B1
(en)
|
2012-10-18 |
2022-03-30 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
DK2956477T4
(da)
|
2013-02-15 |
2024-04-15 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
|
HK1223302A1
(zh)
|
2013-06-28 |
2017-07-28 |
Bioverativ Therapeutics Inc. |
具有xten的凝血酶可裂解连接子和其用途
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EP3048899B1
(en)
|
2013-09-25 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
|
PH12016501323B1
(en)
|
2014-01-10 |
2022-04-29 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
RU2614141C1
(ru)
*
|
2015-12-28 |
2017-03-23 |
федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) |
Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
|
WO2018102743A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
|
US20200031895A1
(en)
|
2016-12-16 |
2020-01-30 |
Biogen Ma Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
|
EP3576762A1
(en)
|
2017-01-31 |
2019-12-11 |
Bioverativ Therapeutics Inc. |
Factor ix fusion proteins and methods of making and using same
|
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
|
TWI904068B
(zh)
|
2017-08-09 |
2025-11-11 |
美商生物化學醫療公司 |
核酸分子及其用途
|
|
SG11202007114VA
(en)
|
2018-02-01 |
2020-08-28 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii
|
|
DK3794024T5
(da)
|
2018-05-14 |
2024-08-19 |
Werewolf Therapeutics Inc |
Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
|
|
EP3794023A1
(en)
|
2018-05-14 |
2021-03-24 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
JP7763589B2
(ja)
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|
|
US12226451B2
(en)
|
2018-07-03 |
2025-02-18 |
Bristol-Myers Squibb Company |
FGF-21 formulations
|
|
WO2020033863A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
AU2019393880A1
(en)
|
2018-12-06 |
2021-07-15 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor IX
|
|
WO2020176478A1
(en)
|
2019-02-25 |
2020-09-03 |
The University Of Chicago |
Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
|
|
MX2021013766A
(es)
|
2019-05-14 |
2022-02-21 |
Werewolf Therapeutics Inc |
Restos de separacion y metodos de uso de los mismos.
|
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
|
AU2020384375A1
(en)
|
2019-11-14 |
2022-05-26 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2022072745A1
(en)
*
|
2020-10-01 |
2022-04-07 |
The Regents Of The University Of California |
Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome
|
|
EP4603587A1
(en)
*
|
2022-10-11 |
2025-08-20 |
JCR Pharmaceuticals Co., Ltd. |
Fusion protein of serum albumin and physiologically-active protein
|